VitaDAO
VITAA DAO funding and commercializing longevity research
Performances
RD Popularity Index
RD Growth Index
| 1h | 24h | 7d | 30d | 60d | 90d |
|---|---|---|---|---|---|
| 0.48% | 0.50% | 12.54% | 5.71% | 30.14% | 16.93% |
Comparison
Fundraising
On-chain Holding
| Holding Token | Price | Amount | Total Value |
|---|---|---|---|
| No Data | |||
Top Holders
| Address | Token | Quantity | Percentage | Value |
|---|---|---|---|---|
| 0xd9c6...a1ab |   VITA | 4,718,698.2 | 16.77% | $935.79K |
| VitaDAO: Treasury (5ac2) | VITA | 1,820,549.71 | 6.47% | $361.04K |
| 0x639e...1b68 | VITA | 1,798,042.56 | 6.39% | $356.58K |
Open Markets
| # | Exchange | Pair | Price | +2% depth | -2% depth | Volume (24h) | volume % |
|---|---|---|---|---|---|---|---|
| 1 | VITA/BIO | $0.5181 | $7,447 | $7,425 | $3,828 | 16.71% | |
| 2 | VITA/BIO | $0.5079 | $2,081 | $2,075 | $3,360 | 14.67% | |
| 3 | VITA/CRYO | $0.6049 | $575 | $573 | $44 | 0.19% |
Follow Updates
Follow Lists
People
About VitaDAO
VitaDAO is a blockchain-based collective where members jointly decide how to fund early-stage research on extending healthspan (slowing aging). It converts research outputs into "intellectual property tokens," allowing participants to co-own assets and govern their future development.
It tackles a structural gap in traditional drug R&D: early research is hard to fund, and resulting IP is often concentrated in large companies, leading to high prices and low transparency. By enabling direct public funding and keeping IP community-owned, VitaDAO aims to make longevity research more open and equitable.
In the past six months, its model gained wider recognition—a U.S. White House science report cited DAOs as entities that directly fund research. Among its funded projects, ARTAN Bio's suppressor tRNA technology generated first animal data, with first-in-human studies planned for late 2027/early 2028; it also launched a consumer cosmetics line to support further research.
Positive: ARTAN Bio (VitaRNA IP-NFT) closed a $1M seed round (June 2026) and joined spARK Labs, advancing toward FIH studies (late 2027/early 2028). VitaApp launched for biological age tracking (July 2026), adding a consumer product. VitaLabs Season 2 focused on decisiveness.
Negative: VITA price fell ~97% from ATH to $0.22, with only $4K–$16K daily volume (illiquidity). 57.7% of supply unminted (governance-controlled dilution risk). Next unlock May 1, 2026 released 823,830 VITA ($182K). No buyback/burn or revenue-sharing mechanisms reported.
Paul Kohlhaas
Core contributor and co-founder of VitaDAO. He is also the founder of Molecule and served as CEO. Previously, he held roles at ConsenSys (Director of Business Development) and Linum Labs (Founder & CEO). He studied Economics & International Affairs at the University of St.Gallen. His LinkedIn: https://www.linkedin.com/in/kohlhaas, Twitter: https://x.com/paulkhls.